Ilevro (Nepafenac) Patent Expiration, LOE Window & CMS Spending

Ilevro (Nepafenac) by Harrow Eye: FDA Orange Book LOE 2032-03-31, 0 AB generics, $15.6M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHarrow Eye
FDA Application & PathwayN203491 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-03-31
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$15.6M
2024 Medicare Part D Spend$14.9M
2024 Medicaid Spend$763K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 24.8% 2-yr change)